Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and / or TGR-1202 Trials
Trial Status: Enrolling by Invitation
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and / or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
- Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
- Subjects must have completed at least 6 cycles of therapy on their current protocol.
- Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.
University of Nebraska Medical Center
Trial Phase Phase II
Trial Type Treatment
TG Therapeutics Inc
- Primary ID UTX-TGR-501
- Secondary IDs NCI-2019-00763
- Clinicaltrials.gov ID NCT03207256